Changshan Kaijiejian Biopharmaceutical R & D (Hebei) Co., Ltd.

Primary objective: To evaluate the effect of subcutaneous injection of CJC-1134-PC injection on the pharmacokinetics of metformin, atorvastatin, and warfarin in healthy subjects, and to provide a scientific basis for the clinical combination of CJC-1134-PC injection. Secondary objectives: 1. To evaluate the effect of subcutaneous injection of CJC-1134-PC injection on the pharmacodynamics of warfarin in healthy subjects; 2. To evaluate the safety of subcutaneous injection of CJC-1134-PC injection in combination with metformin, atorvastatin, and warfarin in healthy subjects.

Primary objective: To evaluate the efficacy of CJC-1134-PC injection once a week for 24 weeks compared with placebo in patients with type 2 diabetes who have poor glycemic control after treatment with metformin alone or metformin combined with insulin secretagogues. Secondary objective: To evaluate the efficacy of CJC-1134-PC injection once a week for 24 weeks compared with placebo in patients with type 2 diabetes who have poor glycemic control after treatment with metformin alone or metformin combined with insulin secretagogues: 1. Safety of continuous administration for 24 weeks compared with placebo; 2. Efficacy of continuous administration for 28 and 52 weeks; 3. Safety of continuous administration for 28 and 52 weeks.

Primary objective: To evaluate the efficacy of CJC-1134-PC injection once a week for 24 weeks compared with placebo in patients with type 2 diabetes and poor glycemic control who are not receiving antidiabetic drugs. Secondary objective: To evaluate the efficacy of CJC-1134-PC injection once a week for 24 weeks compared with placebo in patients with type 2 diabetes and poor glycemic control who are not receiving antidiabetic drugs: 1. Safety of continuous administration for 24 weeks compared with placebo; 2. Efficacy of continuous administration for 28 and 52 weeks; 3. Safety of continuous administration for 28 and 52 weeks.